Yulei Wang

TL;DR: In patients with unresectable hepatocellular carcinoma, atezolIZumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib.

TL;DR: Tumours from a large cohort of patients with metastatic urothelial cancer who were treated with an anti-PD-L1 agent were examined and major determinants of clinical outcome were identified and suggested that TGFβ shapes the tumour microenvironment to restrain anti-tumour immunity by restricting T-cell infiltration.

TL;DR: It is found that most cells can be rescued from drug sensitivity by simply exposing them to one or more RTK ligands, and the observation that hepatocyte growth factor confers resistance to the BRAF inhibitor PLX4032 in BRAF-mutant melanoma cells is among the findings with clinical implications.

TL;DR: Primary endpoints were confirmed objective response rate in all patients who received the combination treatment for group A and progression-free survival in the intention-to-treat population in group F, both assessed by an independent review facility according to Response Evaluation Criteria in Solid Tumors version 1.1.

TL;DR: In this article, the authors provided a high-resolution dissection of the entire tumor ecosystem through single-cell RNA-sequencing analysis of 15 ovarian tumors, and revealed chemokine receptor-ligand interactions within and across compartments as potential mechanisms mediating immune cell infiltration.